Immuneering (IMRX) Research & Development (2020 - 2026)

Immuneering's Research & Development history runs 7 years deep, the most recent figure standing at $10.6 million for Q1 2026.

• On a quarterly basis, Research & Development fell 7.2% year-over-year to $10.6 million in Q1 2026; TTM through Mar 2026 was $41.2 million, a 14.54% decrease from a year earlier, with the FY2025 full-year figure at $42.0 million, down 12.33% from the prior year.
• Research & Development advanced to $10.6 million in Q1 2026 per IMRX's latest filing, from $9.3 million in the prior quarter.
• Across five years, Research & Development topped out at $14.9 million in Q4 2024 and bottomed at $8.0 million in Q2 2022.
• The 5-year median for Research & Development is $10.5 million (2025), against an average of $10.5 million.
• Across the five-year window, Research & Development jumped 68.03% in 2022 and tumbled 37.71% in 2025, its largest moves.
• Year by year, Research & Development stood at $9.9 million in 2022, then rose by 20.65% to $11.9 million in 2023, then gained by 24.74% to $14.9 million in 2024, then tumbled by 37.71% to $9.3 million in 2025, then grew by 15.03% to $10.6 million in 2026.
• Per Business Quant, the three latest IMRX Research & Development figures stand at $10.6 million (Q1 2026), $9.3 million (Q4 2025), and $10.9 million (Q3 2025).